Hv1 Modulators and Uses

Tech ID: 30417 / UC Case 2019-915-0

Brief Description

Researchers at UCI have engineered a class of Hv1 polypeptide modulators that selectively modulate Hv1 voltage gated channels while leaving other voltage gated channels unaffected. With no Hv1 modulators currently on the market, this class of Hv1 polypeptide modulators could provide solutions in birth control, autoimmune therapies, and tumor reduction.

Suggested uses

·Birth Control – Inhibition of sperm maturation

·Autoimmune Therapies -Reducing reactive oxygen species (ROS) in white blood cells

·Cancer Therapeutics - Tumor reduction

Features/Benefits

·Polypeptides selectively target only Hv1 voltage gated channels

·Includes both reversible and irreversible modulators

·Cell type specific response

·Effective at inhibiting ROS production in white blood cells and sperm capacitation in μM range

Full Description

Cells use voltage gated channels to create gradients which are used for important cellular functions. The ability to modulate these voltage gated channels allows for control of important cellular functions. The Hv1 voltage gated channel is an attractive therapeutic target due to its high expression in some metastatic cancers, its role in sperm maturation, and its use by white blood cells to produce reactive oxygen species for inflammatory responses. Currently no selective Hv1 channel inhibitors are on the market.

Researchers at UCI have developed a class of polypeptides that act as selective Hv1 channel modulators. These polypeptides can reversibly or irreversibly inhibit the Hv1 channel. The unique structure of the modulators allows them to selectively target the Hv1 channel while leaving other voltage gated channels unaffected.The polypeptide modulators can also have their amino acid sequence tailored to fine-tune the channel inhibition.Preliminary results have shown efficacy for limiting ROS production and sperm maturation at μM concentrations. The UCI Hv1 polypeptide modulator shows promise for applications in birth control, autoimmune therapy, and cancer.

State Of Development

In vivo and in vitro studies are currently in progress to identify which embodiment is most effective for delivery in humans.

Patent Status

Country Type Number Dated Case
Patent Cooperation Treaty Reference for National Filings 2018126111 07/05/2018 2019-915
 

Patent Pending

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Goldstein, Steven A.N.

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2019, The Regents of the University of California
Terms of use | Privacy Notice